Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Bone Therapeutics
Bone Therapeutics
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Regulatory
Bone Therapeutics enters reverse merger discussions with Medsenic
Bone Therapeutics would remain a Belgian listed company and own 51% of the share capital of Medsenic
Research & Development
Bone Therapeutics refocuses on lead clinical asset
A number of actions have been taken to reduce the company’s cost base and enable completion of a Phase IIb study on ALLOB
Finance
Catalent to acquire facility from Bone Therapeutics
In addition to the expansion in Gosselies, validation of Catalent’s new 32,000 sqft cell therapy development facility in Houston, Texas is underway
Pharmaceutical
Bone Therapeutics invests in cell therapy manufacturing facility
New Belgian plant should be fully operational by 2015
Subscribe now